Virtu Financial LLC Buys Shares of 88,982 Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Virtu Financial LLC purchased a new position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 88,982 shares of the biopharmaceutical company’s stock, valued at approximately $66,000.

Other large investors also recently modified their holdings of the company. Intech Investment Management LLC purchased a new position in Lexicon Pharmaceuticals in the third quarter worth about $115,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Lexicon Pharmaceuticals by 4.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,417,295 shares of the biopharmaceutical company’s stock worth $2,225,000 after purchasing an additional 58,147 shares during the period. FMR LLC boosted its holdings in shares of Lexicon Pharmaceuticals by 28.9% in the third quarter. FMR LLC now owns 49,867,042 shares of the biopharmaceutical company’s stock worth $78,291,000 after buying an additional 11,179,919 shares during the last quarter. BNP Paribas Financial Markets grew its position in Lexicon Pharmaceuticals by 71.2% during the third quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 13,246 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Lexicon Pharmaceuticals during the third quarter valued at approximately $189,000. Institutional investors own 74.70% of the company’s stock.

Analysts Set New Price Targets

LXRX has been the topic of several analyst reports. Leerink Partners reiterated a “market perform” rating and set a $1.00 price target (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a research note on Tuesday, March 4th. Leerink Partnrs lowered Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Monday, March 3rd. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Friday. Finally, StockNews.com assumed coverage on shares of Lexicon Pharmaceuticals in a report on Friday. They issued a “sell” rating for the company. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $3.67.

Lexicon Pharmaceuticals Price Performance

Shares of Lexicon Pharmaceuticals stock opened at $0.46 on Tuesday. The company has a market capitalization of $113.47 million, a price-to-earnings ratio of -0.61 and a beta of 1.04. The company has a quick ratio of 7.43, a current ratio of 7.45 and a debt-to-equity ratio of 0.56. The stock’s 50-day simple moving average is $0.60 and its 200-day simple moving average is $0.98. Lexicon Pharmaceuticals, Inc. has a 52 week low of $0.28 and a 52 week high of $2.45.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.02. The business had revenue of $26.55 million during the quarter, compared to the consensus estimate of $6.48 million. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. As a group, analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current fiscal year.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.